<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">Future strategies for CHB treatment will probably continue to include oral NAs in patients who are at risk for disease progression or for HBV reactivation prophylaxis
 <sup>
  <xref ref-type="bibr" rid="CR31">31</xref>
 </sup>. However, the impact of drug combinations in causing additive or synergistic mitochondrial toxicity 
 <italic>in vitro</italic> has not been studied and the experience in patients with CHB is also limited
 <sup>
  <xref ref-type="bibr" rid="CR32">32</xref>
 </sup>. Lamivudine, for example, is currently not indicated for CHB treatment, but is still recommended and widely used for prolonged prophylaxis in patients with different forms of immunodeficiency. A recent Chinese study, showed a reduction in the risk of reactivation in patients with lymphoma treated with a combination of adefovir/lamivudine, when compared to lamivudine alone
 <sup>
  <xref ref-type="bibr" rid="CR33">33</xref>
 </sup>. Therefore, the use of 1
 <sup>st</sup> generation NAs also in combination is still frequent in some countries.
</p>
